

Francois Alhenc-Gelas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/850664/publications.pdf>

Version: 2024-02-01

23
papers

1,056
citations

394421

19
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

901
citing authors

#	ARTICLE	IF	CITATIONS
1	Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Prostaglandins, 1982, 24, 723-742.	1.2	137
2	Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT2Receptors. Circulation Research, 2004, 94, 1623-1629.	4.5	83
3	Cardiovascular Phenotypes of Kinin B2Receptor and Tissue Kallikrein Deficient Mice. Hypertension, 2002, 40, 90-95.	2.7	75
4	Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB Journal, 2005, 19, 1172-1174.	0.5	71
5	Loss-of-Function Polymorphism of the Human Kallikrein Gene with Reduced Urinary Kallikrein Activity. Journal of the American Society of Nephrology: JASN, 2002, 13, 968-976.	6.1	69
6	Critical Role of Tissue Kallikrein in Vessel Formation and Maturation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 657-664.	2.4	64
7	Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. Journal of Clinical Investigation, 2005, 115, 780-787.	8.2	64
8	Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney International, 2009, 76, 395-403.	5.2	55
9	Tissue Kallikrein Deficient Mice Display a Defect in Renal Tubular Calcium Absorption. Journal of the American Society of Nephrology: JASN, 2005, 16, 3602-3610.	6.1	54
10	Tissue Kallikrein Is Essential for Invasive Capacity of Circulating Proangiogenic Cells. Circulation Research, 2011, 108, 284-293.	4.5	50
11	Selective Kinin Receptor Agonists as Cardioprotective Agents in Myocardial Ischemia and Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 23-30.	2.5	48
12	Negative Cooperativity in the Human Bradykinin B2Receptor. Journal of Biological Chemistry, 1998, 273, 1309-1315.	3.4	46
13	Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 210-216.	2.5	46
14	Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. Journal of Clinical Investigation, 2005, 115, 780-787.	8.2	28
15	Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thrombosis and Haemostasis, 2013, 110, 476-483.	3.4	26
16	Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. European Journal of Heart Failure, 2008, 10, 343-351.	7.1	23
17	Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases. Current Pharmaceutical Design, 2011, 17, 2654-2662.	1.9	21
18	Partial Human Genetic Deficiency in Tissue Kallikrein Activity and Renal Calcium Handling. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 320-325.	4.5	19

#	ARTICLE	IF	CITATIONS
19	Kinin Receptor Agonism Restores Hindlimb Postischemic Neovascularization Capacity in Diabetic Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 218-226.	2.5	19
20	Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. <i>Clinical Science</i> , 2016, 130, 45-56.	4.3	19
21	Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. <i>Frontiers in Medicine</i> , 2019, 6, 136.	2.6	16
22	Kinins and Kinin Receptors in Cardiovascular and Renal Diseases. <i>Pharmaceuticals</i> , 2021, 14, 240.	3.8	13
23	Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice. <i>Scientific Reports</i> , 2017, 7, 9410.	3.3	10